Search
Sumario de resultados
TIpos de contenido
Fecha
-
NewOryzon announces presentation of final data from PORTICO, vafidemstat’s global Phase IIb ...
Seleccionada para presentación oral. La conferencia se celebrará en Milán del 21-23 de septiembre.
-
NewAseBio and the Ministry of Health analyze the challenges and opportunities of Artificial I...
The event "Challenges and Opportunities for Spain in the Application of AI in Health Data Spaces," organized by AseBio together with the Ministry of Health, brought together leading organizations from
-
Press releaseAseBio and the Ministry of Health analyze the challenges and opportunities of Artificial I...
The event "Challenges and Opportunities for Spain in the Application of AI in Health Data Spaces," organized by AseBio together with the Ministry of Health, brought together leading organizations from
-
CompanyAROSA I + D
-
NewOvercoming Challenges in the Current Biotech Landscape
Biotech entrepreneurs have experienced a demanding drug development environment in the last 24 months. To succeed, biotech leaders must overcome challenges associated with planning, fundraising, and
-
NewAlira Health Publishes a White Paper on the Impact of New European Union Regulations on Ad...
It provides an overview of the key changes that will impact access to innovative medicines and advanced therapies in the EU.
-
New#NewAseBioMember | “AseBio gives us access to key resources, and potential collaborations ...
Meet ASPARIA GLYCOMICS, our new member. We talked to its Ane Rodrigo, Sales & Marketing Manager.
-
CompanyTELOMERE THERAPEUTICS
-
CompanyLIFESOME THERAPEUTICS
-
NewORYZON presents preliminary data from ongoing Phase Ib FRIDA trial with iadademstat plus ...
Data from the first two cohorts demonstrated that combination of iadademstat plus gilteritinib was safe and showed strong antileukemic activity. A third cohort is ongoing following FDA’s OPTIMUS
-
New#NewAseBioMember | “AseBio represents an essential platform for collaboration, networking ...
Meet Paralab Bio, our new member. We talked to its Andrea Zapater, Bio Product Specialist.
-
Press releaseInvestment in R&D by biotech companies grows by 17% to 1,218 million euros
In 2022, the activity of biotech companies in Spain generated more than 16.6 billion euros in revenue, representing 1.5% of the national GDP. Private funding raised by the sector reached an all-time
-
NewInvestment in R&D by biotech companies grows by 17% to 1,218 million euros
Private funding raised by the sector reached an all-time high, surpassing 228 million euros after a 37% increase.
-
CompanyONENA MEDICINES
-
-
Press releaseBiotechnology revolutionizes early detection of prostate cancer, the incidence of which co...
Biotechnology is central to the diagnosis, treatment and follow-up of prostate cancer and plays a broad role across the spectrum of patient care. Telomere measurement technology represents a useful
-
NewBiotechnology and bio-manufacturing win 350 million euros in support and investment from E...
The European Commission thus reinforces biotechnology as central to Europe's green, digital and long-term industrial transition.
-
NewRafael Simó: "We should talk about "obesities" instead of "obesity" because more and more...
Geneis Biomed interviews Dr. Rafael Simón, head of the Endocrinology and Nutrition Department at Vall d'Hebron University Hospital and Director of the Diabetes and Metabolism Research Unit at Vall d
-
CompanyASPARIA GLYCOMICS
-
NewBiotechnology: key to addressing the triple environmental crisis and achieving the Sustain...
Biotechnology addresses environmental challenges through bioremediation, the production of renewable energy, sustainable agriculture, or the reduction of greenhouse gas emissions.
-
Press releaseBiotechnology: key to addressing the triple environmental crisis and achieving the Sustain...
Biotechnology addresses environmental challenges through bioremediation, the production of renewable energy, sustainable agriculture, or the reduction of greenhouse gas emissions. Biofuels are one of